Document:

Strictly Confidential	 	Execution Copy

 

 

 

 

 

 

REGISTRATION RIGHTS AGREEMENT

 

between

 

CHINA CORD BLOOD CORPORATION

 

and

 

CORDLIFE GROUP LIMITED

 

 

Dated November 12, 2012

 

 

 

 

 

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	Page
	 	 
	Section 1 DEFINITIONS	1
	 	 
	Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT	5
	 	 
	Section 3 MANDATORY REGISTRATION	5
	 	 
	Section 4 DEMAND REGISTRATION RIGHTS	8
	 	 
	Section 5 INCIDENTAL OR “PIGGY-BACK” REGISTRATION	9
	 	 
	Section 6 UNDERWRITTEN OFFERINGS	10
	 	 
	Section 7 REGISTRATION PROCEDURES	12
	 	 
	Section 8 INDEMNIFICATION; CONTRIBUTION	17
	 	 
	Section 9 COVENANTS	20
	 	 
	Section 10 MISCELLANEOUS	21

 

    	 

    	 

    

 

REGISTRATION RIGHTS AGREEMENT (this
“Agreement”) made on November 12, 2012

 

BETWEEN:

 

		(1)	CHINA CORD BLOOD CORPORATION, an exempted company with limited liability incorporated in
the Cayman Islands with its registered office at Codan Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, PO Box 2681,
Grand Cayman KY1-1111, Cayman Islands (the “Company”); and

 

		(2)	CORDLIFE GROUP LIMITED, a company limited by shares incorporated
in Singapore with its registered office at 61 Science Park Road, #05-16/18 The Galen, Singapore Science Park II, Singapore 117525
(the “Investor”).  

 

Capitalized terms used herein and not otherwise
defined shall have the meanings ascribed to them in Section 1 hereof.

 

RECITALS:

 

		 	(A)            WHEREAS,
                                                                                                                              pursuant to the Share Purchase Agreement dated as of August 15, 2012 (the “Purchase Agreement”) by and
                                                                                                                              between the Company and the Investor, the Company has agreed to sell to the Investor 7,314,015 ordinary shares of the
                                                                                                                              Company (the “Sale Shares”), par value US$0.0001 per share.

 

		 	(B)           
WHEREAS, in connection therewith, and in order to induce the Investor to purchase the Sale Shares, the Company desires to
and has agreed to grant to the Investor the demand and other registration rights set forth herein.

 

		 	(C)           
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows.

 

AGREEMENT:

 

Section
1

DEFINITIONS

 

		1.1.	Definitions.  As used in this Agreement, and unless the context requires a different
meaning, the following terms have the meanings indicated:

 

“Affiliate”
means any Person who is an “affiliate” as defined in Rule 12b-2 of the General Rules and Regulations under the Exchange
Act.

 

“Agreement”
means this Agreement as the same may be amended, supplemented or modified in accordance with the terms hereof.

 

“Asian/European Listing”
has the meaning set forth in Section 9.2(a).

 

    	1

    	 

    
 

“Asian/European Public
Offering” has the meaning set forth in Section 9.2(c).

 

“Board of Directors”
means the board of directors of the Company.

 

“Business Day”
means any day other than a Saturday, Sunday or other day on which commercial banks in the State of New York are required or authorized
by law or executive order to be closed.

 

“Charter Documents”
means the memorandum and articles of association of the Company, as may be amended from time to time.

 

“Ordinary Shares”
mean the ordinary shares, par value US$0.0001 per share, of the Company and any other equity securities of the Company into which
such ordinary shares are reclassified or reconstituted, and any equity securities of the Company or any successor which may be
issued on or after the date hereof in respect of, or in exchange for, ordinary shares pursuant to, among others, merger, consolidation,
share split, share dividend, recapitalization of the Company or otherwise.

 

“Ordinary Shares Equivalents”
mean any security or obligation which is by its terms, directly or indirectly, substantively analogous to, convertible into or
exchangeable or exercisable into or for Ordinary Shares, and any option, warrant or other subscription or purchase right with respect
to Ordinary Shares.

 

“Company”
has the meaning set forth in the preamble to this Agreement.

 

“Company Underwriter”
has the meaning set forth in Section 5.1.

 

“Completion Date”
has the meaning set forth in the Purchase Agreement.

 

“Demand Request”
has the meaning set forth in Section 4.1.

 

“Designated Holder”
means the Investor and any permitted transferee of the Investor to whom Registrable Securities have been transferred in accordance
with Section 10.4 of this Agreement, other than a transferee to whom Registrable Securities have been transferred pursuant to a
Registration Statement under the Securities Act or Rule 144 or Regulation S under the Securities Act (or any successor rules thereto),
but in each case solely for so long as the Investor or transferee continues to be a holder of Registrable Securities.

 

“Electing Holders”
has the meaning set forth in Section 6.1.

 

“Eligible Market”
has the meaning set forth in the definition of “Trading Day” as set forth in this Section 1.

 

“Effectiveness Period”
has the meaning set forth in Section 3.2(a).

 

    	2

    	 

    
 

“Event” has
the meaning set forth in Section 3.3.

 

“Event Payment Date”
has the meaning set forth in Section 3.3.

 

“Event Payments”
has the meaning set forth in Section 3.3.

 

“Exchange Act”
means the US Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC thereunder.

 

“FINRA” means
the Financial Industry Regulatory Authority (or any successor entity thereto). 

 

“Governmental Authority”
means any government or political subdivision thereof; any department, agency or instrumentality of any government or political
subdivision thereof; any court or arbitral tribunal; and the governing body of any securities exchange or other self-regulatory
body, whether domestic or foreign.

 

“Holders’ Counsel”
has the meaning set forth in Section 7.1(a).

 

“Incidental Registration”
has the meaning set forth in Section 5.1.

 

“Indemnified Party”
has the meaning set forth in Section 8.3.

 

“Indemnifying Party”
has the meaning set forth in Section 8.3.

 

“Investor”
has the meaning set forth in the preamble to this Agreement.

 

“Inspector”
has the meaning set forth in Section 6.2(b).

 

“Liability”
has the meaning set forth in Section 8.1.

 

“Majority Interest”
means the Designated Holders holding at least a majority of the then-outstanding Registrable Securities.

 

“Other Shareholders”
has the meaning set forth in Section 5.1.

 

“Participating Holder”
has the meaning set forth in Section 6.1.

 

“Person” means
any natural person, firm, company, Governmental Authority, joint venture, partnership, association or other entity (whether or
not having separate legal personality).

 

“Purchase Agreement”
has the meaning set forth in the recitals to this Agreement.

 

“Records”
has the meaning set forth in Section 6.2(b).

 

“Registrable Securities”
means (i) any Sale Shares; and (ii) any other Ordinary Shares issued or issuable in respect of the shares described in subsection
(i) above (because of stock splits, stock dividends, combination of shares, reclassifications, recapitalizations, mergers, consolidations
or other reorganization or similar events and any Ordinary Shares issuable upon conversion, exercise or exchange thereof). As to
any particular Registrable Securities, such securities shall cease to be Registrable Securities when (i) a Registration Statement
covering such Registrable Securities has been declared effective under the Securities Act by the SEC and such Registrable Securities
have been disposed of pursuant to such effective Registration Statement, (ii) the entire amount of the Registrable Securities owned
by a Designated Holder may be sold in one transaction without any limitation as to volume pursuant to Rule 144 (or any successor
provision then in effect) under the Securities Act in the opinion of counsel satisfactory to the Company and such Designated Holder,
each in their reasonable judgment or (iii) such Registrable Securities have been sold pursuant to Rule 144 under the Securities
Act.

 

    	3

    	 

    
 

“Registration Expenses”
has the meaning set forth in Section 7.3.

 

“Registration Statement”
means a registration statement filed pursuant to the Securities Act.

 

“Required Effectiveness
Date” means the earlier of (i) the date that is forty-five (45) days from the Required Filing Date; provided, that, if
the SEC reviews and has comments to the filed Registration Statement, then the Required Effectiveness Date under this clause shall
be ninety (90) days from the Required Filing Date, or (ii) five (5) Business Days following the date the SEC or the Staff notifies
the Company that it will not review the Registration Statement or that the Company may request effectiveness of the Registration
Statement.

 

“Required Filing Date”
has the meaning set forth in Section 3.1.

 

“SEC” means
the United States Securities and Exchange Commission or any similar or successor agency then having jurisdiction to enforce the
Securities Act.

 

“SEC Approved Registrable
Securities” means Registrable Securities other than SEC Non-Registrable Securities.

 

“SEC Non-Registrable
Securities” means the Registrable Securities excluded from the Registration Statement either (i) pursuant to Section
3.2(b) because the SEC or the Staff has indicated through comment letters or otherwise that such securities are not eligible to
be resold under Rule 415 of the Securities Act, or (ii) pursuant to Section 3.2(c).

 

“Securities Act”
means the US Securities Act of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder.

 

“Shelf Registration
Statement” has the meaning set forth in Section 3.1.

 

“Staff” has
the meaning set forth in Section 3.2(b).

 

    	4

    	 

    
 

“Trading Day”
means (i) any day on which the Ordinary Shares are listed or quoted and traded on any national securities exchange, market or trading
or quotation facility on which the Ordinary Shares are then listed or quoted (an “Eligible Market”), or (ii)
if the Ordinary Shares are not then listed or quoted and traded on any Eligible Market, then a day on which trading occurs on the
OTC Bulletin Board (or any successor thereto), or (iii) if trading ceases to occur on the OTC Bulletin Board (or any successor
thereto), any Business Day.

 

“Underwriter Identification”
has the meaning set forth in Section 3.2(b).

 

Section
2

GENERAL;
SECURITIES SUBJECT TO THIS AGREEMENT

 

		2.1.	Grant of Rights.  The Company hereby grants registration rights to the Designated
Holders upon the terms and conditions set forth in this Agreement.

 

Section
3

MANDATORY
REGISTRATION

 

		3.1.	Shelf Registration Statement.  Not later than sixty (60) days after the Investor
written demand (such 60th day, the “Required Filing Date”), the Company shall file with the SEC a registration
statement pursuant to Rule 415 of the Securities Act (a “Shelf Registration Statement”) on Form F-3 (or any
successor form thereto), or if Form F-3 may not be used by the Company pursuant to applicable law, on Form F-1 (or any successor
form thereto), with respect to the resale, from time to time, of all of the Registrable Securities held by the Designated Holders,
provided that such demand is with respect to at least one million of such Registrable Securities. The disposition of Registrable
Securities from the Shelf Registration Statement may occur, at any time, in one or more underwritten offerings, block transactions,
broker transactions, at-market transactions or in such other manner or manners as may be specified by the applicable Designated
Holders. Notwithstanding the above, if the Company is required to file the Registration Statement on a Form F-1, then the Company
shall have ninety (90) days from the date of request from the Designated Holders to prepare and file the Registration Statement
and the Required Filing Date shall be, in such case, the ninetieth (90th) day after the request from the Designated Holders

 

		3.2.	Effective Shelf Registration Statement.

 

		(a)	The Company shall use its commercially reasonable efforts to cause the Shelf Registration Statement
to become effective as soon as practicable, and shall use its commercially reasonable efforts to keep the Shelf Registration Statement
continuously effective under the Securities Act, subject to the provisions of Sections 7.4 and 7.5 hereof, until the earlier of
(i) such time as all Registrable Securities registered thereunder are eligible for sale by a Designated Holder in the open market
in a single transaction pursuant to Rule 144 of the Securities Act (or any similar provision then in force) without being subject
to the volume limitations thereof or (ii) all Registrable Securities covered by such Shelf Registration Statement have been
sold pursuant to such Shelf Registration Statement or pursuant to Rule 144 or otherwise pursuant an applicable exemption from the
registration requirements of the Securities Act (such period being the “Effectiveness Period”).

 

    	5

    	 

    
 

		(b)	Notwithstanding anything to the contrary in this Agreement (other than Section 3.2(d) below), in
the event the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering pursuant to a Registration
Statement filed pursuant to this Agreement as constituting an offering of securities by or on behalf of the Company such that Rule
415 is not available to the Company to register the resale of such Registrable Securities and, as a result, the Staff or the SEC
does not permit such Registration Statement to become effective and used for resales in a manner that permits the continuous resale
at the market by the Designated Holders participating therein (or as otherwise may be acceptable to each Designated Holder) without
being named therein as an “underwriter,” then the Company shall reduce the number of shares to be included in such
Registration Statement (in accordance with the following sentence) until such time as the Staff and the SEC shall so permit such
Registration Statement to become effective as aforesaid. In making such reduction, the Company shall reduce the number of
Registrable Securities to be included by all other Designated Holders on a pro rata basis (based upon the number of Registrable
Securities otherwise required to be included for each such Designated Holder) unless the inclusion of shares by a particular Designated
Holder or a particular set of Designated Holders results in the Staff or the SEC’s taking the position that the inclusion
of such Registrable Securities by such Designated Holders would constitute a registration “by or on behalf of the Company,”
in which event, the shares held by such Designated Holder or set of Designated Holders shall be the only shares subject to reduction.  In
addition, in the event that the Staff or the SEC requires any Designated Holder seeking to sell securities under a Registration
Statement filed pursuant to this Agreement to be specifically identified as an “underwriter” (an “Underwriter
Identification”) in order to permit such Registration Statement to become effective, and such Designated Holder (subject
to Section 3.2(d) below) does not consent to being so named as an underwriter in such Registration Statement, then, in each such
case, the Company shall reduce the total number of Registrable Securities to be registered on behalf of such Designated Holder,
only to the extent necessary as would cause the Staff or the SEC not to require such Underwriter Identification or until such Designated
Holder accepts such Underwriter Identification and the manner thereof.  In the event of any reduction in Registrable
Securities pursuant to this Section 3.2(b), if requested by a Designated Holder holding Registrable Securities that were so excluded
from such registration, the Company shall use its reasonable best efforts to cause such Registrable Securities to be registered
to the greatest extent and at the earliest opportunity practicable and in any event not later than sixty (60) days after the earliest
practicable date permitted under applicable guidance of the SEC and the Staff (and shall use its reasonable best efforts to effect
additional registrations of Registrable Securities until all such securities have been included in additional Registration Statements).

 

    	6

    	 

    
 

		(c)	Notwithstanding anything to the contrary in this Agreement, a Designated Holder shall have the
right to require the Company to exclude all or any portion of such Designated Holder’s Registrable Securities from any Registration
Statement, by written notice to the Company upon such Designated Holder’s reasonable belief that (i) inclusion of such Registrable
Securities in the Registration Statement could subject such Designated Holder to underwriter liability, or (ii) the SEC or the
Staff will impose material restrictions and terms on the disposition of such Registrable Securities.  In such event,
the Company shall be required to file a new Registration Statement for such excluded shares in accordance with Section 3.2(b).

 

		(d)	If any such Registration Statement and related prospectus refer to any Designated Holder by name
or otherwise as the holder of any securities of the Company and if in such holder’s sole and exclusive judgment, such holder
is or might be deemed to be an underwriter or a controlling person of the Company, or that such reference could reasonably be expected
to result in an Underwriting Identification requirement, such holder shall have the right to (i) require the insertion therein
of language, in form and substance satisfactory to such holder and presented to the Company in writing, to the effect that the
holding by such holder of such securities is not to be construed as a recommendation by such holder of the investment quality of
the Company’s securities covered thereby and that such holding does not imply that such holder will assist in meeting any
future financial requirements of the Company, or (ii) in the event that such reference to such holder by name or otherwise is not
required by the Securities Act or any similar federal statute then in force, require the deletion of the reference to such holder.

 

		3.3.	Event Payments.  Should an Event (as defined below) occur then, upon each monthly
anniversary of the occurrence of such Event (an “Event Payment Date”) until the applicable Event is cured, as
relief for the damages suffered therefrom by the Designated Holder (the parties hereto agreeing that the liquidated damages provided
for in this Section 3.3 constitute a reasonable estimate of the damages that may be incurred by the Designated Holder by reason
of such Event and that such liquidated damages represent the exclusive monetary remedy for the Designated Holders for damages suffered
due to such Event; provided, however, that this shall in no manner limit the Designated Holders’ entitlement to specific
performance as provided for in Section 10.2), the Company shall pay to the Designated Holder an amount in cash, as liquidated
damages and not as a penalty, equal to one-twentieth of a percent (0.05%) of (i) the number of SEC Approved Registrable Securities
then held by the Designated Holder as of the date of such Event, multiplied by (ii) the purchase price paid by the Designated Holder
for such SEC Approved Registrable Securities then held, for each day that such Event continues, excluding the day on which such
Event has been cured.  The payments to which the Designated Holder shall be entitled pursuant to this Section 3.3 are
referred to herein as “Event Payments.”  In the event the Company fails to make Event Payments to
the Designated Holder within five (5) Business Days after an Event Payment Date, such Event Payments owed to the Designated Holder
shall bear interest at the rate of one half percent (0.5%) per month (prorated for partial months) until paid in full.  All
pro rated calculations made pursuant to this paragraph shall be based upon the actual number of days in such pro rated month.  Notwithstanding
the foregoing provisions, in no event shall the Company be obligated to pay such liquidated damages in an aggregate amount that
exceeds five percent (5.0%) of the purchase price paid by the Designated Holder for its Registrable Securities pursuant to the
Purchase Agreement.

 

    	7

    	 

    
 

For such purposes, each of the
following shall constitute an “Event”:

 

		 	(a)              
a Registration Statement is not filed on or prior to the Required Filing Date or is not declared effective on or prior to
the Required Effectiveness Date except: (i) as provided for in Section 7.4 or (ii) in the event that the SEC or the Staff (whether
by means of a comment letter provided by the SEC or the Staff relating to the Registration Statement or otherwise) makes a determination
that the registration of the Registrable Securities under the Registration Statement may not be appropriately characterized as
secondary offerings that are eligible to be made on a shelf basis under Rule 415 or that one or more of the Designated Holders
should be subjected to Underwriter Identification; or

 

		 	(b)              
on and after the effective date of a Registration Statement filed hereunder, a Designated Holder is not permitted to sell
SEC Approved Registrable Securities under the Registration Statement (or a subsequent Registration Statement filed in replacement
thereof) for any reason (other than the fault of such Designated Holder or in compliance with applicable rules and regulations
such as insider trading policies) for more than forty five (45) days in any one hundred and eighty day (180) day period or for
more than ninety (90) days in any twelve month period.

 

		3.4.	Expenses.  The Company shall bear all Registration Expenses in connection with
this Section 3, whether or not the Shelf Registration Statement becomes effective.

 

Section
4

DEMAND
REGISTRATION RIGHTS

 

		4.1.	If, at any time after the Required Filing Date and prior to the expiration of the Effectiveness
Period, (i) (A) additional Registrable Securities, which have not been included in the Shelf Registration Statement of the Company
pursuant to Section 3.1 above, are issued or issuable to, or otherwise acquired by, the Designated Holder or its Affiliates or
(B) a Registration Statement covering the sale of all of the Registrable Securities is not then effective and available for sales
thereof by the Designated Holder, and (ii) the Company receives from the Designated Holder a written request (the “Demand
Request”) stating that such Designated Holder is likely to be considered an Affiliate of the Company and requesting that
the Company effect a registration with respect to at least one million of such Registrable Securities (which request shall state
the number of shares of Registrable Securities to be disposed of and the intended methods of disposition of such shares by the
Designated Holder), the Company shall as soon as practicable, file and use reasonable best efforts to effect up to three such registrations
during the period from the Required Filing Date to the expiration of the Effectiveness Period (but not more frequently than once
per 180 day period) and to permit or facilitate the sale and distribution of all of such Registrable Securities.

 

    	8

    	 

    
 

		4.2.	Expenses.  The Company shall bear all Registration Expenses in connection with this Section
4, whether or not a Registration Statement becomes effective.

 

Section
5

INCIDENTAL
OR “PIGGY-BACK” REGISTRATION

 

		5.1.	Request for Incidental Registration.  At any time after the date hereof until
the end of the Effectiveness Period, if (i) the Company proposes to file a Registration Statement under the Securities Act with
respect to an offering by the Company for its own account (other than a Registration Statement on Form F-4 or S-8 or any successor
thereto), or (ii) the Company proposes to file a Registration Statement under the Securities Act with respect to an offering for
the account of any shareholder of the Company other than any Designated Holder, then in each case the Company shall give written
notice of such proposed filing to each of the Designated Holders at least fifteen (15) days before the anticipated filing date,
and such notice shall specify, at minimum, the proposed date of filing of such Registration Statement, any proposed means of distribution
of such Registrable Securities or other securities, any proposed managing underwriter or underwriters of such Registrable Securities
or other securities and offer such Designated Holders the opportunity to register the number of Registrable Securities as each
such Designated Holder may request (an “Incidental Registration”).  The Company shall use its reasonable
best efforts (within twenty (20) days of the notice by the Designated Holders provided for below in this sentence) to cause the
managing underwriter or underwriters in the case of a proposed underwritten offering (the “Company Underwriter”)
to permit each of the Designated Holders who have requested in writing to the Company within ten (10) Business Days of the giving
of the notice by the Company to participate in the Incidental Registration to include its, his or her Registrable Securities in
such offering on the same terms and conditions as the securities of the Company or the account of such other shareholder, as the
case may be, included therein.  In connection with any Incidental Registration under this Section 5.1 involving an underwritten
offering, the Company shall not be required to include any Registrable Securities in such underwritten offering unless the Designated
Holders thereof accept the terms of the underwritten offering as agreed upon between the Company, such other shareholders, if any,
and the Company Underwriter.  If the Company Underwriter determines that the registration of all or part of the Registrable
Securities which the Designated Holders have requested to be included in an offering by the Company for its own account (other
than a Registration Statement on Form F-4 or S-8 or any successor thereto) would materially adversely affect the price, timing
or distribution of the securities offered or the price per security that will derive from such registration, then the Company shall
be required to include in such Incidental Registration, to the extent of the amount that the Company Underwriter believes may be
sold without causing such adverse effect, (i) all of the securities to be offered for the account of the Company, (ii) the Registrable
Securities to be offered for the account of the Designated Holders pursuant to this SECTION 5, as a group, which Registrable Securities
shall be allocated pro rata among such Designated Holders based on the number of Registrable Securities requested to be included
in such offering by each such Designated Holder and (iii) other securities requested to be included in such offering; provided,
however, that no such reduction shall reduce the shares of Registrable Securities held by the Designated Holders included in
the registration to below 20% of the total amount of securities included in such registration, unless such adverse effect is related
to any of the matters contemplated by Section 3.2(b) hereof, in which case such 20% floor shall not apply and such Registrable
Securities may be excluded pursuant to the provisions of Section 3.2(b) hereof.  If the Company Underwriter determines
in writing that the registration of all or part of the Registrable Securities which the Designated Holders have requested to be
included in an offering for the account of any shareholder of the Company other than any Designated Holders (“Other Shareholders”)
would materially adversely affect the price, timing or distribution of the securities offered or the price per security that will
derive from such registration, then the Company shall be required to include in such Incidental Registration, to the extent of
the amount that the Company Underwriter believes may be sold without causing such adverse effect, (i) all of the securities to
be offered for the account of such Other Shareholders, (ii) the Registrable Securities to be offered for the account of the Designated
Holders pursuant to this SECTION 5, as a group, which Registrable Securities shall be allocated pro rata among such other Designated
Holders based on the number of Registrable Securities requested to be included in such offering by each such Designated Holder,
(iii) all of the securities to be offered for the account of the Company, and (iv) other securities requested to be included in
such offering; provided, however, that no such reduction shall reduce the shares of Registrable Securities held by the Designated
Holders included in the registration to below 40% of the total amount of securities included in such registration unless such adverse
effect is related to any of the matters contemplated by Section 3.2(b) above, in which case such 40% floor shall not apply and
such Registrable Securities may be excluded pursuant to the provisions of Section 3.2(b).  For the avoidance of doubt,
no registration pursuant to this Section 5.1 shall relieve the Company of its obligations to register Registrable Securities pursuant
to Sections 3.1, 3.2 and 5.1.

 

    	9

    	 

    
 

		5.2.	Right to Terminate Registration.  The Company shall have the right to terminate
or withdraw any registration initiated by it under Section 5.1 prior to the effectiveness of such registration whether or not any
Designated Holder has elected to include Registrable Securities in such registration.  A Designated Holder shall have
the right, by written notice to the Company, to exclude all or any portion of such Designated Holder’s Registrable Securities
from any Registration Statement effected pursuant to this Section 5 at any time prior to its effectiveness.

 

		5.3.	Expenses.  The Company shall bear all Registration Expenses in connection with
any Incidental Registration pursuant to this Section 5, whether or not such Incidental Registration becomes effective.

 

Section
6

UNDERWRITTEN
OFFERINGS

 

		6.1.	Market Underwritten Offering.  The Designated Holders may distribute all or any
portion of the Registrable Securities then held by them by means of an underwritten offering; provided, that: (i) a Majority
Interest has requested such underwritten offering (the “Electing Holders”); (ii) the Electing Holders provide
written notice to the Company and the other Designated Holders of their intention to distribute Registrable Securities by means
of an underwritten offering; (iii) the managing underwriter or underwriters thereof shall be jointly designated by the Company
and the Electing Holders; (iv) each Designated Holder participating in such underwritten offering (each a, “Participating
Holder” and collectively, the “Participating Holders”) agrees to sell such Participating Holder’s
Registrable Securities on the basis provided in any underwriting arrangements approved by the Electing Holders entitled selecting
the managing underwriter or underwriters hereunder;  (v) each Participating Holder participating in such underwritten
offering completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents
reasonably required under the terms of such underwriting arrangements; (vi) the Company shall be entitled to include securities
in such underwritten offering amounting to not less than 20% of the aggregate offering; and (vii) the underwritten sale pursuant
to this Section must be for a number of Registrable Securities, which based on the good faith determination by the Electing Holders,
would result in gross proceeds of at least $20 million (excluding securities to be offered for the account of the Company).

 

		6.2.	The Company agrees that in the event an underwritten offering pursuant to Section 6.1 is undertaken,
the Company shall (without limitation to the obligations of the Company set forth in Section 7):

 

		 	(a)              
enter into and perform customary agreements (including an indemnity agreement with customary indemnification provisions)
and take such other actions as reasonably required in order to expedite or facilitate the disposition of such Registrable Securities,
including causing its officers to participate in “road shows” and other information meetings organized by the underwriter,
if applicable;

 

    	10

    	 

    
 

		 	(b)              
make available at reasonable times for inspection by any Designated Holder, any managing underwriter participating in any
disposition of such Registrable Securities pursuant to a Registration Statement, Holders’ Counsel and any attorney retained
by any such Designated Holder or any managing underwriter (each, an “Inspector” and, collectively, the “Inspectors”),
all financial and other records, pertinent corporate documents and properties of the Company and its subsidiaries, and such other
information (collectively, the “Records”) as shall be reasonably necessary to enable any such Inspector to exercise
their due diligence responsibility, and cause the Company’s and its subsidiaries’ officers, directors and employees,
and the independent public accountants of the Company, to supply all information reasonably requested by any such Inspector in
connection with such Registration Statement.  Notwithstanding the foregoing, Records and other information that the Company
determines, in good faith, to be confidential, and which is delivered to the Inspectors pursuant to written instruction to keep
such information confidential, shall not be disclosed by the Inspectors or used for any purpose other than as necessary or appropriate
for the purpose of such inspection (and the Inspectors shall confirm their agreement in writing in advance to the Company if the
Company shall so request) unless (i) the disclosure of such Records is necessary, in the Company’s judgment, to avoid or
correct a misstatement or omission in the Registration Statement, (ii) the release of such Records is ordered pursuant to a subpoena
or other order from a court of competent jurisdiction after exhaustion of all appeals therefrom or (iii) the information in such
Records was and/or becomes otherwise known to the Inspectors on a non-confidential basis, prior to or after its disclosure by the
Company, or was and/or becomes generally available to the public.  Each Designated Holder agrees that it shall promptly,
upon learning that disclosure of such Records is sought in a court of competent jurisdiction, give notice to the Company and allow
the Company, at the Company’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential,
and such Designated Holder shall reasonably cooperate with the Company in connection therewith;

 

		 	(c)              
furnish, at the request of any seller of Registrable Securities on the date such securities are delivered to the underwriters
for sale pursuant to such registration or, if such securities are not being sold through underwriters, on the date the Registration
Statement with respect to such securities becomes effective and dated as of such date, an opinion of counsel representing the Company
for the purposes of such registration, addressed to the underwriters, if any, and to the seller making such request, covering such
legal matters with respect to the registration in respect of which such opinion is being given as the underwriters, if any, and
such seller may reasonably request and are customarily included in such opinions; and

 

    	11

    	 

    
 

		 	(d)              
obtain one or more “cold comfort” letters, dated the effective date of such Registration Statement and dated
the date of the closing under the applicable underwriting agreement, signed by the independent certified public accountants of
the Company who have certified the financial statements included in such Registration Statement, in customary form and covering
such matters of the type customarily covered by “cold comfort” letters as the holders of a Majority Interest may request.

 

Section
7

REGISTRATION
PROCEDURES

 

		7.1.	Obligations of the Company.  Whenever registration of Registrable Securities is
required or requested pursuant to this Agreement, the Company shall use its commercially reasonable efforts to effect the registration
of such Registrable Securities in accordance with the intended method of distribution thereof, and in connection with any such
request, the Company shall, as expeditiously as possible:

 

		 	(a)              
before filing a Registration Statement or prospectus or any amendments or supplements thereto relating to Registrable Securities,
the Company shall provide a single counsel selected by the Designated Holders holding a majority of the Registrable Securities
being registered in such registration (“Holders’ Counsel”) with an adequate and appropriate opportunity
to review and comment on such Registration Statement and each prospectus included therein (and each amendment or supplement thereto)
to be filed with the SEC, subject to such documents being under the Company’s control.  The Company shall reasonably
cooperate with Holders’ Counsel in performing the Company’s obligations under this Agreement.  The Company
shall promptly notify the Holders’ Counsel and each seller of Registrable Securities of any stop order issued or threatened
by the SEC relating to Registrable Securities and take all actions required to prevent the entry of such stop order or to remove
it if entered;

 

		 	(b)              
prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in
connection therewith as may be necessary to keep such Registration Statement effective for the period specified in Section 3, and
if not so specified therein, the lesser of (i) one hundred and eighty (180) days and (ii) such shorter period which will terminate
when all Registrable Securities covered by such Registration Statement have been sold and shall comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such Registration Statement during such period in accordance
with the intended methods of disposition by the sellers thereof set forth in such Registration Statement;

 

		 	(c)              
furnish to each seller of Registrable Securities, prior to filing a Registration Statement relating to Registrable Securities,
at least one executed copy of such Registration Statement as is proposed to be filed, and thereafter such number of conformed copies
of such Registration Statement, each amendment and supplement thereto (in each case including all exhibits thereto), the prospectus
included in such Registration Statement (including each preliminary prospectus and any summary prospectus) and such other documents
or prospectus as each such seller may reasonably request in order to facilitate the public sale or other disposition of the Registrable
Securities owned by such seller;

 

    	12

    	 

    
 

		 	(d)              
register or qualify such Registrable Securities under such other securities or “blue sky” laws of such jurisdictions
as any seller of Registrable Securities may reasonably request, and continue such registration or qualification in effect in such
jurisdiction for as long as permissible pursuant to the laws of such jurisdiction, or for as long as any such seller reasonably
requests or until all of such Registrable Securities are sold, whichever is shortest, and do any and all other acts and things
which may be reasonably necessary or advisable to enable any such seller to consummate the public sale or other disposition in
such jurisdictions of the Registrable Securities owned by such seller; provided, however, that the Company shall
not be required to (i) qualify generally to do business as a foreign entity in any jurisdiction where it would not otherwise be
required to qualify but for this Section 7.1(d), or (ii) consent to general service of process in any such jurisdiction;

 

		 	(e)              
promptly notify each seller of Registrable Securities: (i) when a prospectus, any prospectus supplement, a Registration
Statement or a post-effective amendment to a Registration Statement (but only if relating to Registrable Securities) has been filed
with the SEC, and, with respect to a Registration Statement or any post-effective amendment (but only if relating to Registrable
Securities), when the same has become effective; (ii) of any comments or request by the SEC or any other federal or state Governmental
Authority for amendments or supplements to a Registration Statement or related prospectus or for additional information (but only
if relating to Registrable Securities); (iii) of the issuance by the SEC or any other Governmental Authority of any stop order
suspending the effectiveness of a Registration Statement relating to Registrable Securities or of any order suspending or preventing
the use of any related prospectus or the initiation or threatening of any proceedings for that purpose; (iv) of the receipt by
the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the
Registrable Securities for sale in any jurisdiction or the initiation or threatening of any proceedings for such purpose; (v) of
the existence of any fact or happening of any event (including the passage of time) of which the Company has knowledge which makes
any statement of a material fact in such Registration Statement or related prospectus or any document incorporated or deemed to
be incorporated therein by reference untrue or which would require the making of any changes to the Registration Statement or prospectus
in order that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the
case of such prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading; and (vi) determination by counsel of the Company that a post-effective amendment to a Registration Statement relating
to Registrable Securities is advisable;

 

    	13

    	 

    
 

		 	(f)              
upon the occurrence of any event contemplated by clause (v) of Section 7.1(e), as promptly as practicable, prepare a supplement,
amendment or post-effective amendment to such Registration Statement or related prospectus and furnish to each seller of Registrable
Securities a reasonable number of copies of such supplement to or an amendment or post-effective amendment of such Registration
Statement or prospectus as may be necessary so that, after delivery to the purchasers of such Registrable Securities, in the case
of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein not misleading, and that in the case of such prospectus, it will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading;

 

		 	(g)              
upon the occurrence of any event contemplated by clauses (iii) or (iv) of Section 7.1(e), as promptly as practicable, use
its reasonable best efforts to promptly obtain the withdrawal of any such order or suspension and shall immediately notify each
seller of Registrable Securities of any such withdrawal;

 

		 	(h)              
cause all such Registrable Securities to be listed on each securities exchange on which similar securities issued by the
Company are then listed; provided, that the applicable listing requirements are satisfied;

 

		 	(i)              
keep Holders’ Counsel reasonably advised in writing as to the initiation and progress of any registration hereunder;
provided, that the Company shall provide Holders’ Counsel with all correspondence with Staff or the SEC in connection
with any Registration Statement filed hereunder to the extent that such Registration Statement has not been declared effective
on or prior to the date required hereunder;

 

		 	(j)              
provide reasonable cooperation to each seller of Registrable Securities and each underwriter participating in the disposition
of such Registrable Securities and their respective counsel in connection with any filings required to be made with the FINRA;

 

		 	(k)              
cooperate with the Designated Holders of the Registrable Shares to facilitate the timely preparation and delivery of certificates
representing such Registrable Shares to be delivered to a transferee pursuant to a Registration Statement, which certificates shall
be free of any restrictive legends and in such denominations and registered in such names as such Designated Holders may request;

 

    	14

    	 

    
 

		 	(l)              
not later than the Required Effectiveness Date of any Registration Statement, provide CUSIP numbers for the Registrable
Securities registered for resale under such Registration Statement, and provide the transfer agent for the Registrable Shares one
or more certificates for such Registrable Shares, in a form eligible for deposit with the Depository Trust Company; and

 

		 	(m)              
take all other steps reasonably necessary and advisable to effect the registration of the Registrable Securities contemplated
hereby.

 

		7.2.	Seller Information.  The Company may require each seller of Registrable Securities
as to which any registration is being effected to furnish, and such seller shall furnish, to the Company such information regarding
the distribution of such securities as the Company may from time to time reasonably request in writing in response to requests
made by the Staff or to permit the Company to comply with the rules and regulations of the SEC.  The furnishing of such
information shall be a condition to the inclusion of the seller’s shares in such registration.

 

		7.3.	Registration Expenses.  The Company shall pay all expenses arising from or incident
to its performance of, or compliance with, this Agreement, including, without limitation, (i) SEC, stock exchange and FINRA registration
and filing fees, (ii) all fees and expenses incurred in complying with securities or “blue sky” laws (including reasonable
fees, charges and disbursements of counsel to any underwriter incurred in connection with “blue sky” qualifications
of the Registrable Securities as may be set forth in any underwriting agreement), (iii) all printing, messenger and delivery expenses,
(iv) the reasonable fees, charges and expenses of the Holders’ Counsel (including without limitation the fees charges and
expenses incurred in connection with any amendments to a Registration Statement) not to exceed US$100,000 per Registration Statement,
and (v) the reasonable fees, charges and expenses of counsel to the Company and of its independent certified public accountants
and any other accounting fees, charges and expenses incurred by the Company (including, without limitation, any expenses arising
from any “cold comfort” letters or any special audits incident to or required by any registration or qualification),
regardless of whether such Registration Statement is declared effective.  All of the expenses described in the preceding
sentence of this Section 7.3 are referred to herein as “Registration Expenses.”  The Designated Holders
of Registrable Securities sold pursuant to a Registration Statement shall bear the expense of any broker’s commission or
underwriter’s discount or commission relating to registration and sale of such Designated Holders’ Registrable Securities.

 

		7.4.	Notice to Discontinue.  Each Designated Holder agrees that, upon receipt of any
notice from the Company of the happening of any event of the kind described in clause (v) of Section 7.1(e), such Designated Holder
shall forthwith discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable
Securities until such Designated Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by
Section 7.1(f) and, if so directed by the Company, such Designated Holder shall deliver to the Company (at the Company’s
expense) all copies, other than permanent file copies then in such Designated Holder’s possession, of the prospectus covering
such Registrable Securities which is current at the time of receipt of such notice.  If the Company shall give any such
notice, the Company shall extend the period during which such Registration Statement shall be maintained effective pursuant to
this Agreement (including, without limitation, the period referred to in Section 7.1(b) by the number of days during the period
from and including the date of the giving of such notice pursuant to clause (v) of Section 7.1(e) to and including the date when
sellers of such Registrable Securities under such Registration Statement shall have received the copies of the supplemented or
amended prospectus contemplated by, and meeting the requirements of, Section 7.1(f) provided, that, no single suspension
under this Section 7.4 shall exceed forty-five (45) days in any one hundred and eight (180) day period and in no event shall more
than one suspension event exceed, in the aggregate, sixty (60) days in any twelve (12) month period.

 

    	15

    	 

    
 

		7.5.	Suspension of Sales.  Notwithstanding anything in this Agreement to the contrary,
so long as the Registration Statement is on Form F-1 or on any other form that does not allow for forward incorporation by reference
of reports and other materials filed by the Company pursuant to Section 13(a) or 15(d) of the Exchange Act, the Company may suspend
sales under such Registration Statement as follows (but, in any event, no single suspension event shall exceed forty-five (45)
days in any one hundred and eighty (180) day period) and in no event shall more than one suspension event exceed, in the aggregate,
sixty (60) days in any twelve (12) month period: (i) for the period commencing at the time that the Company disseminates a press
release announcing its preliminary financial results for any fiscal period and ending on the third (3rd) Business Day after the
earlier of (A) the date that the related report on Form 20-F under the Exchange Act is filed with the SEC and (B) the date on which
such report is required to be filed under the Exchange Act (giving effect to Rule 12b-25 promulgated thereunder); (ii) for the
period commencing at the time that the Company disseminates a press release announcing a material development that would make a
statement of a material fact in such Registration Statement untrue or misleading and ending on the third (3rd) Business Day after
the earlier of (A) the date that the related report on Form 6-K is filed with the SEC and (B) the date on which such report is
required to be filed under the Exchange Act (giving effect to Rule 12b-25 promulgated thereunder); (iii) to the extent necessary
to allow any post-effective amendment to the Registration Statement or supplement to the prospectus to be prepared and, if necessary,
filed with the SEC and, in the case of a post-effective amendment, declared effective; and (iv) for a period during which
the Company, in the good faith opinion of the Board of Directors, determines that the disclosure of material, non-public information
concerning the Company or any of its subsidiaries would be materially detrimental to the Company; provided, that the Company
shall promptly notify the Designated Holders in writing (I) of the existence of such material, non-public information (provided
that in each notice the Company will not disclose the content of such material, non-public information to the Designated Holders)
and the date on which such suspension will begin and (II) of the date on which such suspension ends.

 

    	16

    	 

    

 

Section
8

INDEMNIFICATION;
CONTRIBUTION

 

		8.1.	Indemnification by the Company.  The Company agrees to indemnify and hold harmless
(to the fullest extent permitted by applicable law) each Designated Holder, its general or limited partners, members, directors,
officers, Affiliates and each Person who controls (within the meaning of Section 15 of the Securities Act) any of the foregoing
to the fullest extent permitted by applicable law from and against any and all losses, claims, damages, liabilities and expenses
(including reasonable costs of investigation) or any action or proceeding in respect thereof (including reasonable costs of investigation
and reasonable attorneys’ fees and expenses) (each, a “Liability” and collectively, “Liabilities”),
(i) arising out of or based upon or relating to any untrue, or allegedly untrue, statement of a material fact contained in any
Registration Statement, prospectus or preliminary, final or summary prospectus, or document incorporated by reference into any
of the foregoing (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto), (ii) arising
out of or based upon any omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading in the light of the circumstances under which such statements were made, except insofar
as such Liability arises out of or is based upon any untrue statement or omission contained in such Registration Statement, preliminary
prospectus or final prospectus in reliance and in conformity with information concerning such Designated Holder furnished in writing
to the Company by such Designated Holder specifically for use therein, or (iii) any violation or alleged violation by the Company
of the Securities Act, the Exchange Act, any state securities laws or any rule or regulation promulgated under the Securities Act,
the Exchange Act or any state securities laws in connection with the sale of securities by such Designated Holder pursuant to any
Registration Statement in which such Designated Holder is participating.  The Company shall also provide customary indemnities
to any underwriters (or persons, including broker-dealers or agents deemed “underwriters” within the meaning of the
Securities Act) of the Registrable Securities, their officers, directors and employees and each Person who controls such underwriters
(within the meaning of Section 15 of the Securities Act) to the same extent as provided above with respect to the indemnification
of the Designated Holders of Registrable Securities.

 

		8.2.	Indemnification by Designated Holders.  In connection with any Registration Statement
in which a Designated Holder is participating pursuant to Section 3 or Section 5 hereof, each such Designated Holder shall promptly
furnish to the Company in writing such information with respect to such Designated Holder as may be required by law or regulation
for use in connection with any such Registration Statement or prospectus and all information required to be disclosed in order
to make the information previously furnished to the Company by such Designated Holder not materially misleading or necessary to
cause such Registration Statement or prospectus not to omit a material fact with respect to such Designated Holder necessary in
order to make the statements therein not misleading.  Each Designated Holder agrees to indemnify and hold harmless the
Company, its directors, officers, Affiliates, and each Person who controls the Company to the same extent as the foregoing indemnity
from the Company to the Designated Holders, but only if such untrue statement or omission was made in reliance upon and in conformity
with information with respect to such Designated Holder furnished in writing to the Company by such Designated Holder specifically
for use in such Registration Statement or preliminary, final or summary prospectus or amendment or supplement, or a document incorporated
by reference into any of the foregoing; provided, however, that the total amount to be indemnified by such Designated
Holder pursuant to this Section 8.2 shall be limited to the net proceeds (after deducting the underwriters’ discounts and
commissions) received by such Designated Holder in the offering to which the Registration Statement or prospectus relates.

 

    	17

    	 

    
 

		8.3.	Conduct of Indemnification Proceedings.  Any Person entitled to indemnification
hereunder (the “Indemnified Party”) agrees to give prompt written notice to the indemnifying party (the “Indemnifying
Party”) after the receipt by the Indemnified Party of any written notice of the commencement of any action, suit, proceeding
or investigation or threat thereof made in writing for which the Indemnified Party intends to claim indemnification or contribution
pursuant to this Agreement; provided, however, that the failure to so notify the Indemnifying Party shall not relieve
the Indemnifying Party of any Liability that it may have to the Indemnified Party hereunder (except to the extent that the Indemnifying
Party is materially prejudiced or otherwise forfeits substantive rights or defenses by reason of such failure).  If notice
of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party shall be entitled
to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume the defense
of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party.  The
Indemnified Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be paid by the Indemnified Party unless (i) the Indemnifying Party agrees to pay the
same, (ii) the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory to the Indemnified
Party or (iii) such parties have been advised in writing by such counsel that either (x) representation of such Indemnified Party
and the Indemnifying Party by the same counsel would be inappropriate under applicable standards of professional conduct or (y)
there may be one or more legal defenses available to the Indemnified Party which are different from or additional to those available
to the Indemnifying Party, in any of such cases, the Indemnifying Party shall not have the right to assume the defense of such
action on behalf of such Indemnified Party, it being understood, however, that the Indemnifying Party shall not be liable for the
fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) for all similarly-situated Indemnified
Parties.  No Indemnifying Party shall be liable for any settlement entered into without its written consent, which consent
shall not be unreasonably withheld.  No Indemnifying Party shall, without the consent of such Indemnified Party, effect
any settlement of any pending or threatened proceeding in respect of which such Indemnified Party is a party and indemnity has
been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Party
from all liability for claims that are the subject matter of such proceeding.

 

    	18

    	 

    
 

		8.4.	Contribution.

 

		 	(a)             
If the indemnification provided for in this Section 8 from the Indemnifying Party is unavailable to an Indemnified Party
hereunder in respect of any Liabilities referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified
Party, shall contribute (to the fullest extent permitted by applicable law) to the amount paid or payable by such Indemnified Party
as a result of such Liabilities in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and
Indemnified Party in connection with the actions which resulted in such Liabilities, as well as any other relevant equitable considerations.  The
relative faults of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether
any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to
state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action.  The
amount paid or payable by a party as a result of the Liabilities referred to above shall be deemed to include, subject to the limitations
set forth in Sections 8.1 and 8.2, any legal or other fees, charges or expenses reasonably incurred by such party in connection
with any investigation or proceeding; provided, that the total amount to be contributed by such Designated Holder shall
be limited to the net proceeds (after deducting the underwriters’ discounts and commissions) received by such Designated
Holder in the offering.

 

		 	(b)             
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 8.4 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred
to in Section 8.4(a).  No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.

 

    	19

    	 

    
 

Section
9

COVENANTS

 

		9.1.	Rule 144.  The Company covenants that from and after the date hereof it shall
use its best efforts to (i) timely file any reports required to be filed by it under the Exchange Act and (ii) promptly take such
further action as each Designated Holder may reasonably request (including providing any information necessary to comply with Rule
144 under the Securities Act), all to the extent required from time to time to enable such Designated Holder to sell Registrable
Securities without registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 under
the Securities Act, as such rule may be amended from time to time or (ii) any similar rules or regulations hereafter adopted by
the SEC.  The Company shall, upon the request of any Designated Holder, deliver to such Designated Holder a written statement
as to whether it has complied with such requirements.

 

		9.2.	Other Listings.

 

		 	(a)             
In addition to the rights of the Designated Holders under Section 3, Section 4, Section 5 and Section 6 of this Agreement,
in the event of the admission or listing of any Ordinary Shares of the Company or in the form of Depositary Receipts to or a stock
exchange located in Asia or Europe (a “Asian/European Listing”), the Company shall take such action as may be necessary
or required to include in such Asian/European Listing all Registrable Securities held by the Designated Holders and to enable Designated
Holders to freely resell such Registrable Securities to the same extent as any other holder of Ordinary Shares of the Company on
such securities exchange, and to maintain any such Asian/European Listing, subject to any “close periods” under the
rules of such securities exchange.

 

		 	(b)             
Without limiting the generality of subsection (a), the Company shall take such action, including, without limitation, preparing,
printing and circulating prospectus, listing particulars and other offering documents setting forth current information regarding
the Company, to the extent reasonably required to facilitate and permit the offering and sale of Registrable Securities by, and
on behalf of, the Designated Holders on such securities exchange.

 

		 	(c)             
If any part of the equity share capital of the Company is to be offered in Asia or Europe by the Company or any of its shareholders
in a manner requiring the publication of a prospectus or listing particulars (an “Asian/European Public Offering”)
pursuant to a firm commitment underwriting, the Company shall (i) each such time give written notice to the Designated Holders
of its intention to do so and (ii) use its reasonable best efforts to include in such Asian/European Public Offering all of the
Registrable Securities held by such Designated Holders from whom the Company has received written request for inclusion thereof
within ten (10) Business Days of the receipt by such Designated Holders of the notice referred to in clause (i) above, to the same
extent as provided by the incidental or “piggy-back” rights held by the Designated Holders pursuant to Section 5.

 

    	20

    	 

    
 

		 	(d)             
The Company shall pay all expenses arising from or incident to its performance of, or compliance with, this Section 9.2,
including, without limitation, (i) listing, filing and other fees required to effect a Asian/European Listing or Asian/European
Public Offering, (ii) all fees and expenses incurred in complying with securities laws or rules of the applicable jurisdiction
or stock exchange (including reasonable fees, charges and disbursements of counsel to any underwriter incurred in connection with
such compliance as may be set forth in any underwriting agreement), (iii) all printing, messenger and delivery expenses, (iv) the
fees, charges and disbursements of counsel to the Company and of its independent public accountants and any other accounting fees,
charges and expenses incurred by the Company (including, without limitation, any expenses arising from any “cold comfort”
letters or any special audits incident to or required by any Asian/European Listing or Asian/European Public Offering) and any
legal fees, charges and expenses incurred by the Company and the reasonable fees, charges and expenses, if any, of the Designated
Holders’ Counsel not to exceed $50,000, and (v) any liability insurance or other premiums for insurance obtained for the
benefit of the Company and/or its directors and officers in connection with any Asian/European Listing or Asian/European Public
Offering, regardless of whether such Asian/European Listing becomes effective or such Asian/European Public Offering commences.  In
the event any of the Registrable Securities held by the Designated Holders are sold pursuant to an Asian/European Public Offering,
each Designated Holder shall bear the respective expense of any broker’s commission or an underwriter’s discount or
commission relating to the sale of such Designated Holders’ Registrable Securities.

 

		9.3.	Adjustments Affecting Registrable Securities.  The Company shall not take any
action, or permit any change to occur, with respect to its securities that would adversely affect the ability of the Designated
Holders of Registrable Securities to include such Registrable Securities in a registration undertaken pursuant to this Agreement
or that would adversely affect the marketability of such Registrable Securities in any such registration (including, without limitation,
effecting a stock split or a combination of shares).

 

  

Section
10

MISCELLANEOUS

 

		10.1.	Recapitalizations, Exchanges, etc.  The provisions of this Agreement shall apply
to the full extent set forth herein with respect to (i) the Ordinary Shares (including in the form of Depositary Receipts) and
the Ordinary Shares Equivalents, (ii) any and all voting equity securities of the Company into which the Ordinary Shares or Ordinary
Shares Equivalents are converted, exchanged or substituted in any recapitalization or other capital reorganization by the Company
and (iii) any and all equity securities of the Company or any successor or assign of the Company (whether by merger, consolidation,
sale of assets or otherwise) which may be issued in respect of, in conversion of, in exchange for or in substitution of, the Ordinary
Shares or Ordinary Shares Equivalents and shall be appropriately adjusted for any stock dividends, splits, reverse splits, combinations,
recapitalizations and the like occurring after the date hereof.  The Company shall cause any successor or assign (whether
by merger, consolidation, sale of assets or otherwise) to enter into a new registration rights agreement with the Designated Holders
on terms substantially the same as this Agreement as a condition of any such transaction.

 

    	21

    	 

    
 

		10.2.	Remedies.  The Designated Holders, in addition to being entitled to exercise all
rights granted by law, including recovery of damages, shall be entitled to specific performance of their rights under this Agreement.  The
Company agrees that monetary damages alone (including those specified in Section 3.3) would not be adequate compensation for any
loss incurred by reason of a breach by it of the provisions of this Agreement and hereby agrees to waive in any action for specific
performance the defense that a remedy at law would be adequate.

 

		10.3.	Notices.  All notices, demands and other communications provided for or permitted
hereunder shall be made in the manner provided for under the Purchase Agreement.

 

		10.4.	Successors and Assigns; Third Party Beneficiaries.  This Agreement shall inure
to the benefit of and be binding upon the successors and permitted assigns of the parties hereto as hereinafter provided. The rights
of the Designated Holders contained in this Agreement shall be automatically transferred to the transferee of any Registrable Security
provided that (i) such transferee acquires at least one million (1,000,000) Registrable Securities and agrees to become a party
to this Agreement and be fully bound by, and subject to, all of the terms and conditions of the Agreement as though an original
party hereto; (ii) the Company is furnished with written notice of (A) the name and address of such transferee, and (B) the securities
with respect to which such registration rights are being transferred; (iii) immediately following such transfer the further disposition
of such securities by the transferee is restricted under the Securities Act or applicable state securities laws if so required;
and (iv) such transfer shall have been conducted in accordance with all applicable federal and state securities laws.  All
of the obligations of the Company hereunder shall survive any transfer.  Except as provided in Section 8, no Person other
than the parties hereto and their successors and permitted assigns are intended to be a beneficiary of this Agreement.

 

		10.5.	Amendments and Waivers.  Except as otherwise provided herein, the provisions of
this Agreement may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may
not be given unless consented to in writing by (i) the Company and (ii) the Designated Holders holding at least a Majority Interest;
provided that any party hereto may give a waiver in writing as to itself.

 

		10.6.	Aggregation of Shares.  All shares of Registrable Securities held or acquired
by Affiliated entities or Persons or entities or Persons under common management or control shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement.

 

    	22

    	 

    
 

		10.7.	Counterparts.  This Agreement may be executed in one or more counterparts including
counterparts transmitted by telecopier or facsimile, each of which shall be deemed an original, but all of which signed and taken
together, shall constitute one document.

 

		10.8.	Headings.  The headings in this Agreement are for convenience of reference only
and shall not limit or otherwise affect the meaning hereof.

 

		10.9.	GOVERNING LAW; SUBMISSION TO JURISDICTION. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED
IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK OF THE UNITED STATES APPLICABLE TO CONTRACTS TO BE PERFORMED WHOLLY WITHIN
SUCH JURISDICTION, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW OF ANY JURISDICTION.  Each of the parties hereto
(i) shall submit itself to the non-exclusive jurisdiction of any federal court located in the State of New York or any New York
state court having subject matter jurisdiction in the event any dispute arises out of this Agreement, (ii) agrees that venue shall
be proper as to proceedings brought in any such court with respect to such a dispute, (iii) shall not attempt to deny or defeat
such personal jurisdiction or venue by motion or other request for leave from any such court and (iv) agrees to accept service
of process at its address for notices pursuant to this Agreement in any such action or proceeding brought in any such court. With
respect to any such action, service of process upon any Party in the manner provided herein for the giving of notices shall be
deemed, in every respect, effective service of process upon such party.

 

		10.10.	WAIVER OF JURY TRIAL.  BECAUSE DISPUTES ARISING IN CONNECTION WITH COMPLEX FINANCIAL
TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE
AND FEDERAL LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING
SUCH APPLICABLE LAWS.  THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION,
THE PARTIES HERETO WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING BROUGHT TO ENFORCE OR DEFEND ANY RIGHTS OR
REMEDIES UNDER THIS AGREEMENT.

 

		10.11.	Severability.  Each and every obligation under this Agreement shall be treated
as a separate obligation and shall be severally enforceable as such and in the event of any obligation or obligations being or
becoming unenforceable in whole or in part.  To the extent that any provision or provisions of this Agreement are unenforceable
they shall be deemed to be deleted from this Agreement, and any such deletion shall not affect the enforceability of such provisions
of this Agreement as remain not so deleted.

 

    	23

    	 

    
 

		10.12.	Rules of Construction.  Unless the context otherwise requires (i)  the
words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement,
shall refer to this Agreement as a whole and not to any particular provision of this Agreement; (ii) terms defined in the singular
shall have a comparable meaning when used in the plural, and vice versa; (iii) the terms “Dollars,” “dollars”
and “$” mean United States Dollars; (iv) references herein to a specific Section, Subsection, recital, Schedule or
Exhibit shall refer, respectively, to Sections, Subsections, recitals, Schedules or Exhibits of this Agreement; (v) wherever the
word “include,” “includes,” or “including” is used in this Agreement, it shall be deemed to
be followed by the words “without limitation;” (vi) references herein to any gender or no gender shall include each
other gender; (vii) references herein to any Person shall include such Person’s heirs, executors, personal representatives,
administrators, successors and assigns; provided, however, that nothing contained in this clause (viii) is intended
to authorize any assignment or transfer not otherwise permitted by this Agreement; (ix) references herein to a Person in a particular
capacity or capacities shall exclude such Person in any other capacity; (x) with respect to the determination of any period of
time, the word “from” means “from and including” and the words “to” and “until”
each means “to but excluding;” (xi) the word “or” shall be disjunctive but not exclusive; (xii) references
herein to any law (including any federal, state, provincial, local, municipal, foreign, international, multinational, or other
administrative statute, regulation, order, rule, directive, ordinance, code, constitution, principle of common law, equity or treaty)
shall be deemed to refer to such law as amended, modified, codified, reenacted, supplemented or superseded in whole or in part
and in effect from time to time, and also to all rules and regulations promulgated thereunder; (xiii) references to any contract
means such contract as amended, supplemented or modified in accordance with the terms thereof; and (xiv) if the last day for the
giving of any notice or the performance of any act required or permitted under this Agreement is a day that is not a Business Day,
then the time for the giving of such notice or the performance of such action shall be extended to the next succeeding Business
Day.

 

		10.13.	Entire Agreement.  This Agreement is intended by the parties as a final expression
of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto
with respect to the subject matter contained herein.  There are no restrictions, promises, representations, warranties
or undertakings with respect to the subject matter contained herein, other than those set forth or referred to herein.  This
Agreement supersedes all prior agreements and understandings among the parties with respect to such subject matter.

 

		10.14.	Further Assurances.  Each of the parties shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments
and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement
and the consummation of the transactions contemplated hereby.

 

    	24

    	 

    
 

		10.15.	Other Agreements.  Nothing contained in this Agreement shall be deemed to be a
waiver of, or release from, any obligations any party hereto may have under any other agreement including, but not limited to,
the Charter Documents and the Purchase Agreement.

 

		10.16.	Termination.  Except for the liabilities or obligations under Section 7.3 or Section
8, all of which shall remain in effect in accordance with their terms, this Agreement and the obligations of the parties hereunder
(other than liability for the breach by any party hereto of any of the terms of this Agreement) shall terminate upon the end of
the Effectiveness Period.

 

 

[Remainder of page intentionally left blank]

 

    	25

    	 

    

 

IN WITNESS WHEREOF, the undersigned have
executed, or have caused to be executed, this Agreement on the date first written above.

 

	 	CHINA CORD BLOOD CORPORATION
	 	 
	 	By: 	/s/ Albert Chen
	 	 	Name:Albert Chen
Title: Director

	 	CORDLIFE GROUP LIMITED
	 	 
	 	By: 	/s/ Jeremy Pinh Yee
	 	 	Name:Jeremy Pinh Yee
Title: Authorized Signatory

Signature Page to Registration Rights
AgreementStrictly Confidential	 	Execution Copy

 

 

 

 

 

 

DIRECTOR INDEMNIFICATION AGREEMENT

 

between

 

CHINA CORD BLOOD CORPORATION

 

and

 

Jeremy Pinh Yee

 

 

Dated November 12, 2012

 

 

 

 

 

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	Contents	 	Page
	 	 	 
	1.	Interpretation	1
	 	 	 
	2.	Indemnity	3
	 	 	 
	3.	Limitations on Indemnity	4
	 	 	 
	4.	Company’s Liability	4
	 	 	 
	5.	Continuation of Obligations	5
	 	 	 
	6.	Advancement of Expenses	5
	 	 	 
	7.	Notification and Conduct of Claims	6
	 	 	 
	8.	Directors’ and Officers’ Liability Insurance	7
	 	 	 
	9.	Subrogation	8
	 	 	 
	10.	Miscellaneous	8
	 	 	 
	11.	Governing Law	12

 

 

    	 

    	 

    

 

This DIRECTOR INDEMNIFICATION AGREEMENT
(this “Agreement”) made on November 12, 2012

 

AMONG:

 

		(1)	CHINA CORD BLOOD CORPORATION, an exempted company with limited liability incorporated in
the Cayman Islands with its registered office at Codan Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, PO Box 2681,
Grand Cayman KY1-1111, Cayman Islands (the “Company”); and

 

		(2)	Jeremy Pinh Yee, a citizen of Singapore, and any successor or alternate to his position
as Director (as defined below), of 10 Nim Cresent, Singapore 807693, Singapore (the “Investor Director”).

 

Whereas:

 

		(A)	The Company (i) desires to attract and retain highly qualified individuals such as the Investor
Director, to serve on its Board of Directors (the “Board”) and (ii) in order to induce the Investor Director
to be involved with the Company, wishes to provide the Investor Director with specific contractual assurance of the Investor Director's
rights to full indemnification and advancement of expenses to the fullest extent permitted by applicable law against litigation
risks and expenses arising from his position as a Director (as defined below).

 

		(B)	The Investor Director is relying upon the rights afforded under this Agreement in serving as a
Director.

 

		(C)	In view of the considerations set forth above, the Company desires that the Investor Director be
indemnified by the Company as set forth herein.

 

It is agreed as follows:

 

		1.	Interpretation

 

		1.1.	In this Agreement, unless the context otherwise requires:

 

		1.1.1.	The following words bear the meanings assigned to them below:

 

“Affiliate”
of a Person (the "Subject Person") means (a) in the case of a Person other than a natural person, any other
Person that directly or indirectly Controls, is Controlled by or is under common Control with the Subject Person and (b) in the
case of a natural person, any other Person that directly or indirectly is Controlled by the Subject Person;

 

“Agreement”
shall bear the meaning given to it in the Preamble;

 

“Board” shall
bear the meaning given to it in the Recital;

 

“Business Day”
means any day other than a Saturday, Sunday or other day on which commercial banks in the PRC, Hong Kong, Singapore or New York
City are required or authorized by law or executive order to be closed;

 

    	1

    	 

    
 

“Claim” means
any claim, action, proceeding, investigation, administrative proceedings, demand, judgment or amount made by a person other than
the Investor Director;

 

“Company” shall
bear the meaning given to it in the Preamble;

 

“Director” means
a member of the board of directors of the Company;

 

“Expenses” shall
bear the meaning given to it in Clause 2.1;

 

“Hong Kong”
means the Hong Kong Special Administrative Region of the People’s Republic of China;

 

“Investor” means
Cordlife Group Limited, a company limited by shares incorporated in Singapore.

 

“Investor Director”
shall bear the meaning given to it in the Preamble;

 

“Investor Indemnitors”
shall bear the meaning given to it in Clause 9.2; 

 

“Parties” means
the Investor Director and the Company and “Party” means any one of them; and

 

“PRC” means
the People's Republic of China and for the purpose of this Agreement shall exclude Hong Kong, Taiwan and the Special Administrative
Region of Macau.

 

		1.1.2.	References to a statute or statutory provision include:

 

		(i)	that statute or provision as from time to time modified,
re-enacted or consolidated whether before, on or after the date of this Agreement; and

 

		 	(ii)                 
any subsidiary legislation made from time to time under that statute or statutory provision.

 

		1.1.3.	References to one gender include all genders and references to the singular include the plural
and vice versa.

 

		1.1.4.	References to a company shall include any company, corporation or any body corporate, wherever
incorporated.

 

		1.1.5.	References to a subsidiary of a company shall mean, in respect of any Person (the “Parent”),
any other Person in which the Parent directly or indirectly holds (a) ownership of more than 50% of the shares in issue or other
equity interests or registered capital of such Person or (b) the power to direct the management or policies of such Person, whether
through ownership or voting proxy of the voting power of such Person, through the power to appoint a majority of the members of
the board of directors or similar governing body of such Person, through contractual arrangements or otherwise.

 

    	2

    	 

    
 

		1.1.6.	References to Clauses are to Clauses of this Agreement;

 

		1.1.7.	A conviction, judgment or refusal of relief becomes final if there is no possibility of appeal,
or where there is a possibility of appeal:

 

		(i)	If not appealed against, at the end of the period for
bringing an appeal; or

 

		(ii)	if appealed against, at the time when the appeal (or
any further appeal) is determined and the period for bringing any further appeal has ended or if the appeal is abandoned or otherwise
ceases to have effect.

 

		1.2.	Headings shall be ignored in interpreting this Agreement. 

 

		2.	Indemnity

 

		2.1.	Subject to the provisions of this Agreement and so far as may be permitted by all applicable laws
and statutes from time to time in force, the Investor Director shall be entitled to be indemnified by the Company against:

 

		2.1.1.	all demands, claims, costs, charges, fees, losses, damages, judgment, fines, obligations, expenses
and liabilities of any kind or whatsoever nature which may at any time be made against or incurred by him directly or indirectly
by reason of or in consequence of any Claim arising from the execution and discharge of his duties as a director of the Company,
or in connection thereto; and

 

		2.1.2.	any costs, charges, liability and expenses (including but not limited to reasonable investigative,
legal and other expenses, and any amounts paid in settlement) incurred by him in defending any proceedings, whether civil or criminal,
which relate to anything done or omitted or alleged to have been done or omitted by him as a director of the Company,

 

(collectively, “Expenses”).

 

		2.2.	The Investor Director shall take all reasonable steps to mitigate any loss which, in the absence
of mitigation, might give rise to a claim or demand under this Agreement against the Company. For purposes of this Clause 2.2,
reasonable steps of the Investor Director to mitigate any loss shall not require the initiation of litigation or the incurrence
of material expenditure.

 

    	3

    	 

    
 

		3.	Limitations on indemnity

 

		3.1.	Without prejudice to any other rights or remedies which may be available to the Investor Director,
the indemnity granted by the Company to the Investor Director in Clause 2 shall not extend to any Expenses incurred by the Investor
Director:

 

		3.1.1.	to the Company;

 

		3.1.2.	to pay a fine imposed in criminal proceedings;

 

		3.1.3.	to pay a sum payable to a regulatory authority by way of a penalty or composition in respect of
non-compliance with any requirement of a regulatory nature (however arising);

 

		3.1.4.	in defending any criminal proceedings in which he is convicted, where such conviction is final;
or

 

		3.1.5.	in defending any civil proceedings brought by the Company in which final judgment is given against
him.

 

		3.2.	Furthermore, this indemnity shall not apply:

 

		3.2.1.	to the extent that it is not permitted by, or not consistent with, law or statute from time to
time in force or the rules, regulations or codes of any regulatory or other body from time to time in force;

 

		3.2.2.	to any Expenses made against or incurred by the Investor Director if and to the extent that such
Expenses are attributable to any fraudulent or dishonest act or any fraudulent or dishonest omission on the part of the Investor
Director or any other act of omission which the Investor Director commits knowingly or in the knowledge that the same is wrongful
or improper, and where there has been gross negligence, or wilful default by the Investor Director; or

 

		3.2.3.	where the Investor Director has improperly derived a personal benefit or profit.

 

		4.	Company’s liability

 

		4.1.	If the Company makes any payment pursuant to this Agreement in respect of any of the matters against
which the Investor Director is indemnified in Clause 2, and if it is subsequently determined by a court of competent jurisdiction
or an arbitral tribunal (where such determination is final and is binding on the Investor Director) that liability would attach
to the Investor Director in respect of any fraud, dishonesty, gross negligence, default, breach of duty or breach of trust, then
the Investor Director shall promptly repay to the Company all amounts paid by the Company under this Agreement in connection with
such matter.

 

    	4

    	 

    
 

		5.	Continuation of obligations

 

		5.1.	The indemnity under this Agreement shall cease to be valid and enforceable in respect of acts or
omissions of the Investor Director (within the scope of cover of the indemnity set out in Clauses 2 and 3 above) from the date
of termination, resignation or cessation in any manner whatsoever of the Investor Director from being a Director.

 

		5.2.	For the avoidance of doubt, and as an independent stipulation, the indemnity set out in Clauses
2 and 3 above shall continue to apply, and survive cessation of the indemnity pursuant to this Clause, in respect of all relevant
acts and omissions of the Investor Director prior to cessation.

 

		6.	Advancement of Expenses

 

		6.1.	The Company shall, unless prohibited by applicable law, advance any Expenses incurred by or on
behalf of the Investor Director in connection with any Claim within ten (10) Business Days after the delivery by the Investor Director
to the Company of a statement or statements requesting such advances, together with a reasonably detailed written explanation of
the basis therefore and an itemization of legal fees and disbursements in reasonable detail, from time to time, whether prior to
or after final disposition of any Claim. Such advances shall be unsecured and interest free. The Investor Director shall qualify
for advances, to the fullest extent permitted by applicable law, solely upon the execution and delivery to the Company of an undertaking
providing that the Investor Director shall repay the advance to the extent that it is ultimately determined by a court of competent
jurisdiction from which there is no further right to appeal that the Investor Director is not entitled to be indemnified by the
Company under the provisions of this Agreement or applicable law.

 

		6.2.	If the Company shall be obligated under Clause 6.1 to pay the Expenses of any Claim against the
Investor Director, then subject to Clauses 6.3, 6.4 and 6.5, the Company shall be entitled to assume the defence of such Claim
upon the delivery to the Investor Director of written notice of its election to do so.

 

		6.3.	If the Company elects to assume the defence of such Claim as per Clause 6.2, then unless the plaintiff
or plaintiffs in such Claim include one or more Persons holding, together with his, her or its Affiliates, in the aggregate, a
majority of the combined voting power of the Company’s then outstanding voting securities, the Company shall assume such
defence using a single law firm selected by the Company to represent the Investor Director and other present and former directors
or officers of the Company who are parties to such Claim. The retention of such law firm by the Company shall be subject to prior
written approval by the Investor Director, which approval shall not be unreasonably withheld or delayed. If the Company elects
to assume the defence of such Claim and the plaintiff or plaintiffs in such Claim include one or more Persons holding, together
with his, her or its Affiliates, in the aggregate, a majority of the combined voting power of the Company’s then outstanding
voting securities, then the Company shall assume such defence using a single law firm selected by the Investor Director.

 

    	5

    	 

    
 

		6.4.	After (a) in the case of retention of any such law firm selected by the Company, delivery of the
required notice to the Investor Director, approval of such law firm by the Investor Director and the retention of such law firm
by the Company, or (b) in the case of retention of any such law firm selected by the Investor Director, the completion of such
retention, the Company will not be liable to the Investor Director under this Agreement for any Expenses of any other law firm
incurred by the Investor Director after the date that such first law firm is retained by the Company with respect to the same Claim,
unless (i) the retention of a law firm by the Investor Director has been previously authorized by the Company, (ii) the Investor
Director shall have reasonably concluded that there may be a conflict of interest between either (1) the Company and the Investor
Director or (2) the Investor Director and another present or former director or officer of the Company also represented by such
law firm in the conduct of any such defence, or (iii) the Company shall not, in fact, have retained a law firm to prosecute the
defence of such Claim, or failed to have defended such Claim in good faith, in each of which cases, the Expenses of the law firm
retained by the Investor Director shall be at the expense of the Company. Notwithstanding anything to the contrary in Clauses 6.3
and 6.4, the Investor Director shall have the right to retain a separate law firm in any such Claim at the Investor Director’s
sole expense.

 

		6.5.	Notwithstanding anything to the contrary in Clauses 6.2, 6.3 and 6.4, the Company shall not be
entitled to assume the defence of any Claim brought by or in the right of the Company or as to which the Investor Director shall
have made the conclusion provided for in (ii) of Clause 6.4. Notwithstanding anything to the contrary in Clauses 6.2, 6.3 and 6.4,
in the case of (1) any Claim that is or relates to or has arisen in connection with a criminal action or proceeding, or (b) a Claim
that seeks injunction or equitable relief against the Investor Director, the Investor Director shall be entitled to conduct the
defence of the Claim with counsel of his choice and to make all decisions with respect thereto, in which case the reasonable fees
and expenses of counsel shall be at the expense of the Company.

 

		7.	Notification and conduct of claims

 

		7.1.	The Investor Director will, as soon as reasonably practicable and to the extent not prohibited
by applicable law or legal process, notify the Company in writing of any Claim which may give rise to a claim or demand by the
Investor Director against the Company under this Agreement setting out as much information as is available to the Investor Director
(including details of the person(s) making the Claim, the circumstances which gave rise to it and an estimate of the amount of
the Claim), provided that a delay in giving such notification shall not deprive the Investor Director of any right to be indemnified
under this Agreement unless, and then only to the extent that, (a) such delay is materially prejudicial to the defence of such
Claim, or (b) such claim or demand by the Investor Director against the Company as regards a Claim which has been settled without
the Company’s prior written consent which was not unreasonably withheld, delayed or conditioned.

 

    	6

    	 

    
 

		7.2.	The Company shall not settle, compromise or consent to any Claim, including, without limitation,
any Claim in which it takes the position that the Investor Director is not entitled to indemnification in connection with such
settlement, nor shall the Company settle any claim which would impose any fine or impose any obligation on the Investor Director
or which would not otherwise provide the Investor Director with an express, unconditional and final release from all Claims, in
each case, without the Investor Director’s prior written consent. The Investor Director shall not unreasonably withhold,
delay or condition its consent to any proposed settlement.

 

		7.3.	The Company shall be entitled by notice to the Investor Director to assume sole conduct of all
matters relating to any Claim in accordance with the provisions of Clause 6.2.

 

		7.4.	The Investor Director shall do all such things as the Company may reasonably request in order to
permit the Company fully to exercise its rights under Clauses 7.2 and 7.3, and in particular shall:

 

		7.4.1.	provide the Company with such information and copies of such documents relating to any Claim as
the Company may reasonably request;

 

		7.4.2.	not, without the prior written consent of the Company, make any admission in relation to any Claim,
nor settle, compromise or consent to the entry of any judgment (or offer to do so), with respect to any Claim; and

 

		7.4.3.	assist the Company as it may require in resisting, defending or settling such Claim.

 

		7.5.	Without prejudice to Clause 7.2, if the Investor Director is notified in advance of the Company’s
intention to settle or compromise a Claim and reasonably objects to the terms of such settlement or compromise, the Investor Director
shall have the right to assume the conduct of the defence of the Claim unless the terms thereof provide the Investor Director with
an express, unconditional and final release from all claims.

 

		8.	Directors’ and officers’ liability insurance

 

		8.1.	For the duration of the Investor Director’s appointment as a director of the Company,
the Investor Director shall be covered by any directors’ and officers’ liability insurance policy taken out by the
Company pursuant to and subject to the terms of such policy from time to time in force and to the Company’s policy on such
insurance from time to time.

 

    	7

    	 

    
 

		9.	Subrogation

 

		9.1.	If the Company makes any payment under this Agreement, it shall be subrogated to the extent of
such payment to any right the Investor Director may have for recovery of the amounts so paid from any third-party. The Investor
Director agrees to execute all documents required and do all other acts necessary to effect the foregoing provisions and permit
the Company to enforce the rights so subrogated.

 

		9.2.	Notwithstanding any provision to the contrary in this Agreement, the Company hereby acknowledges
that the Investor Director has certain rights to indemnification, advancement of expenses and/or insurance provided by the Investor
and certain of its Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees that:

 

		9.2.1.	it is the indemnitor of first resort (i.e., its obligations to the Investor Director are primary
and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities
incurred by the Investor Director are secondary);

 

		9.2.2.	it shall be required to advance the full amount of the indemnity granted in Clause 2, without regard
to any rights that the Investor Director may have against the Investor Indemnitors; and

 

		9.2.3.	it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims
against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.

 

The Company further agrees that
no advancement or payment by the Investor Indemnitors on behalf of the Investor Director with respect to any Claim for which the
Investor Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have
a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of the
Investor Director against the Company. The Company and the Investor Director agree that the Investor Indemnitors are express third-party
beneficiaries of the terms of this Clause 9.2.

 

		10.	Miscellaneous

 

		10.1.	Notices

 

Each notice, demand or other
communication given or made under this Agreement shall be in writing in English and delivered or sent to the relevant Party at
its address or fax number as set out below (or such other address or fax number as the addressee has by five (5) Business Days'
prior written notice specified to the other Party). Any notice, demand or other communication given or made by letter between countries
shall be delivered by international commercial overnight delivery service or courier (such as Federal Express or DHL). Any notice,
demand or other communication so addressed to the relevant Party shall be deemed to have been delivered, (i) if delivered in person
or by messenger, when proof of delivery is obtained by the delivering Party; (ii) if sent by post within the same country, on the
third (3rd) Business Day following posting, and if sent by post to another country, on the seventh (7th)
Business Day following posting; and (iii) if given or made by fax, upon dispatch and the receipt of a transmission report confirming
dispatch.

 

    	8

    	 

    
 

The initial address and facsimile
for each Party for the purposes of this Agreement are:

 

	if to the Investor Director:	with a copy to:
	 	 
	
        Cordlife Group Limited

        61 Science Park Road, #05-16/18
        

The Galen, Singapore Science Park 

II, Singapore 117525

        Facsimile: +65 6238 1108

        Attention: Jeremy Yee
	
        Shearman & Sterling

        12th Floor Gloucester Tower

        The Landmark

        15 Queen’s Road Central, Central

        Hong Kong

        Facsimile: +852 2978 8099

        Attention: Shuang Zhao 

 

 

	if to the Company:	with a copy to:
	 	 
	
        China Cord Blood Corporation

        48th Floor, Bank of China Tower,

        1 Garden Road, Central

        Hong Kong

        Facsimile: +852 3605 8103

        Attention: Albert Chen
	
        Loeb & Loeb LLP

        345 Park Avenue

        New York, NY 10154

        USA

        Facsimile: +1 212.407.4990

        Attention: Mitchell S. Nussbaum

 

or to such other address as may
have been furnished in the same manner by any Party to the others.

 

		10.2.	Limitation 

 

No legal action shall be brought
and no cause of action shall be asserted by or in the right of the Company against the Investor Director, the Investor Director’s
estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of accrual
of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted
by the timely filing of a legal action within such five (5) year period; provided, however, that if any shorter period of limitations
is otherwise applicable to any such cause of action, such shorter period shall govern.

 

		10.3.	Invalidity

 

		10.3.1.	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole
or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision is legal, valid
and enforceable and gives effect to the intention of the Parties.

 

    	9

    	 

    
 

		10.3.2.	To the extent it is not possible to delete or modify the provision, in whole or in part, under
Clause 10.3.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable, be deemed not
to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject
to any deletion or modification made under Clause 10.3.1, not be affected.

 

		10.4.	Severability

 

To the extent that any provision
or provisions of this Agreement are unenforceable they shall be deemed to be deleted from this Agreement, and any such deletion
shall not affect the enforceability of this Agreement as remain not so deleted.

 

		10.5.	Variation

 

No variation of this Agreement
shall be effective unless in writing and signed by or on behalf of each of the Parties.

 

		10.6.	Counterparts

 

This Agreement may be entered
into in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

		10.7.	Whole agreement

 

This Agreement contains the whole
agreement between the Parties relating to the subject matter of this Agreement at the date of this Agreement to the exclusion of
any terms implied by law which may be excluded by contract and supersedes any previous written or oral agreement between the Company
and the Investor Director in relation to the matters dealt with in this Agreement.

 

		10.8.	Confidentiality

 

		10.8.1.	The Company and the Investor Director shall treat as strictly confidential and not disclose to
any third-party or use any information received or obtained as a result of entering into or performing this Agreement which relates
to:

 

		(i)	the existence and the provisions of this Agreement; or

 

		(ii)	the negotiations relating to this Agreement.

 

		10.8.2.	Clause 10.8.1 shall not prohibit disclosure or use of any information if and to the extent:

 

		(i)	the disclosure or use is required by law, any regulatory
body or any recognised stock exchange on which the shares of the Company or any Affiliate of the Investor are listed;

 

		(ii)	the disclosure or use is required for the purpose of
any judicial proceedings arising out of this Agreement;

  

    	10

    	 

    
 

		 	(iii)                 
the disclosure is made to professional advisers of the Company or the Investor Director, by the Investor Director to officers,
directors, members, employees and representatives of the Investor or any Affiliate of the Investor and to the internal use by the
Investor or such Affiliates or by the Company to its officers and employees who need to know such information to discharge their
duties, if the recipient is, or agrees in writing to be, subject to confidentiality obligations substantially similar to the foregoing;

 

		 	(iv)                 
the disclosure is made by the Investor Director to any Affiliate of the Investor and is reasonably necessary in connection
with reporting requirements of the Investor or such Affiliate in the ordinary course of business, if the recipient is, or agrees
in writing to be, subject to confidentiality obligations substantially similar to the foregoing;

 

		 	(v)                 
the information is or becomes publicly available (other than by breach of this Agreement); or

 

		 	(vi)                 
the other Party has given prior written approval to the disclosure or use, provided that, to the extent permitted by law,
prior to disclosure or use by the Investor Director of any information pursuant to Clause 10.8.2(i), the Investor Director shall
as soon as practicable notify the Company of such requirement with a view to providing the Company with the opportunity to contest
such disclosure or use or otherwise to agree the timing and content of such disclosure or use.

 

		10.8.3.	The provisions of this Clause 10.8 shall continue to apply after the termination of the Investor
Director’s appointment as a director of the Company without limitation in time.

 

		10.9.	Transmission  

 

This Agreement shall enure to
the benefit of the personal representative(s) of the Investor Director.

 

		10.10.	Assignment

 

		10.10.1.	The Company may not assign the benefit of all or any part of its rights under this Agreement.

 

		10.10.2.	The Investor Director may assign the benefit of all or any part of his rights under this Agreement
to any successor to his position as Director.

 

		10.11.	Further Assurances

 

If any act, resolution, approval
or other procedure is required to allow the Investor Director to be given the full benefit of this Agreement, the Company undertakes
to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that will enable the Investor
Director to be given the full benefit of this Agreement.

 

    	11

    	 

    
 

		11.	Governing law

 

		11.1.	Governing Law. This Agreement shall be governed by, and construed in accordance with, the
laws of the Cayman Islands.

 

[The remainder of this page is intentionally
left blank]

 

    	12

    	 

    

 

 

EXECUTED on the day and year first above written.

 

	 	CHINA CORD BLOOD CORPORATION
	 	 
	 	By: 	/s/ Albert Chen
	 	 	Name: Albert Chen
Title: Director

 

	 	Jeremy Pinh Yee
	 	 
	 	 	/s/ Jeremy Pinh Yee
	 	 	

 

Signature
Page to Director Indemnification Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]